Benitec Biopharma Clinical Trial Data
Benitec Biopharma announced positive interim Phase 1b/2a results for its gene therapy BB-301 in patients with Oculopharyngeal Muscular Dystrophy (OPMD). The data showed a 100% responder rate across both low and high dose cohorts, with the high dose group demonstrating greater relative improvements in throat emptying and swallowing capacity at the 3-month mark.